Enzyme engineering forms the focus of a new £5 million seed funding round secured by Imperagen, a Manchester-based techbio company founded by researchers from the University of Manchester’s Manchester Institute of Biotechnology. PXN Ventures led the round, while IQ Capital and Northern Gritstone joined as participating investors. The latest raise lifted Imperagen’s total funding to £8.5 million and set the company on a path to expand research work, laboratory capabilities, and commercial operations during the next 18 months.
🔑 Key Highlights
- University of Manchester spin-out raised £5 million
- PXN Ventures led the investment round
- Total funding reached £8.5 million
- Guy Levy-Yurista joined as chief executive
- Two enzymes recorded productivity gains after five rounds
Imperagen uses a connected system that combines quantum physics, AI modelling, and laboratory automation to improve enzyme development. The process begins with quantum simulations examining millions of mutation possibilities to estimate predicted characteristics. Those findings shape AI systems designed around individual engineering problems. Automated robotics then test selected outcomes in laboratory conditions, sending experimental results back into the process so future testing can improve over time.
The company describes this feedback process as a system that grows more targeted after every round of experimentation. Laboratory findings help narrow the search for stronger-performing enzyme variants while supporting more predictable development for industrial use. Imperagen said traditional manual screening methods can move slowly and involve higher costs, while other smart-design approaches may struggle to perform reliably under real operating conditions.
Commercial work has already begun across sectors tied to enzyme applications, including a project with a Fortune 500 personal care company preparing a product line. According to Imperagen, its AI-guided platform improved the productivity of two enzymes by 677 times and 572 times across five rounds of testing. The business said future investment will support laboratory growth, research development, and expansion of in-house AI capabilities across pharmaceuticals, life sciences, personal care, sustainable fine chemicals, and industrial biotechnology.
The funding announcement also arrived alongside a leadership appointment, with Guy Levy-Yurista joining as chief executive. Imperagen said he brings experience in technology and life sciences businesses and will lead the company during its next stage of growth. The company, founded in November 2021 by Dr Andrew Almond, Dr Andrew Currin, and Dr Tim Eyes, continues to build on its connection to the University of Manchester’s biotechnology research ecosystem.
📊 What This Means (Our Analysis)
The development highlights how a university-linked company is turning scientific research into a structured process aimed at practical industrial outcomes. By combining simulations, AI systems, and laboratory testing inside a repeating workflow, Imperagen presents a model designed to improve enzyme performance with ongoing experimental feedback rather than isolated testing cycles.
The funding round also signals a wider effort to move technical work into commercial settings. Expansion plans tied to research, hiring, laboratory growth, and market development suggest Imperagen is preparing to scale activity while applying enzyme improvements across sectors already identified by the company.
📌 Our Take: The next chapter for this University of Manchester spin-out will depend on how effectively research-driven systems convert scientific progress into commercial results.